Deutsche Tageszeitung - Evox Therapeutics Acquires Exosome AAV Technology and Intellectual Property

Evox Therapeutics Acquires Exosome AAV Technology and Intellectual Property


Evox Therapeutics Acquires Exosome AAV Technology and Intellectual Property
Evox Therapeutics Acquires Exosome AAV Technology and Intellectual Property

IP bolsters Company’s already dominant and broad position with respect to exosome therapeutics

Change text size:

Acquisition is in line with long-term strategy to improve exosome-mediated delivery to enable novel gene therapies and gene editors

OXFORD, United Kingdom, June 20, 2023 (GLOBE NEWSWIRE) -- Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, has purchased Codiak Biosciences engEx-AAV™ technology platform, including all intellectual property rights therein, as well as secured exclusive access to certain engineering and manufacturing rights associated with it. This technology enables active loading of adeno-associated virus (AAV) into exosomes followed by their release when the AAV-loaded exosomes are delivered into recipient cells. This has been demonstrated to be an effective way to improve AAV delivery, to increase the breadth of expression in pre-clinical models, and to shield AAVs from neutralizing antibodies.

“We are pleased to now own this technology and look forward to applying it in future exosome AAV programs. This acquisition further adds to our dominant intellectual property portfolio of patents that cover key aspects needed to develop and commercialise exosome therapeutics including their design, composition, and manufacture,” said Per Lundin, Ph.D., Chief Business Officer & Co-Founder of Evox Therapeutics. “This is part of our long-term business strategy of leveraging improved exosome-mediated delivery to create and enable genetic medicines such as gene therapy and genome editors”.

About Evox Therapeutics

Evox Therapeutics is a privately held, Oxford-based biotechnology company that is a leader in harnessing and engineering the natural delivery capabilities of extracellular vesicles (EVs), known as exosomes, to develop an entirely new class of therapeutics for the treatment of severe rare diseases. Evox uses its proprietary DeliverEX® technology to engineer exosomes to facilitate drug delivery to organs of interest, including the brain and the central nervous system. Exosome-based drugs have the potential to address some of the limitations of genetic medicines such as gene therapy, gene editing, and RNA therapeutics by enabling safe non-immunogenic repeated delivery to cells and tissues that are currently out of reach using other drug delivery technologies. Evox is backed by leading life sciences venture capital groups including Redmile and OrbiMed, and is supported by a comprehensive intellectual property portfolio.

For enquiries, please contact:

Media:
Simon Conway / Natalie Garland-Collins
[email protected]
+44 (0) 203 727 1000

Evox:
Dr. Antonin de Fougerolles, CEO
[email protected] 
+44 (0) 1865 819140

For further information visit: www.evoxtherapeutics.com


Primary Logo

(P.Hansen--DTZ)

Featured

Emergency Doctors Warn Hospitals Cannot Guarantee Patient Safety This Winter

The Irish Association for Emergency Medicine (IAEM) has issued a stark warning that many hospitals are nearing breaking point and cannot guarantee patient safety as the winter season begins. The association criticized the normalization of treating patients in corridors, stating it must never be accepted as a cost of balancing budgets, while the Irish Nurses and Midwives Organisation highlighted critical staffing shortages.

Outdated Marriage Beliefs Hide Sexual Abuse Among Older South Africans

Deeply rooted cultural beliefs that marriage grants automatic sexual rights are leaving many older South Africans unable to recognize sexual abuse within their relationships. Recent workshops in Gauteng have highlighted how these outdated norms, combined with shame and financial dependence, prevent victims from seeking help or understanding consent.

RCSI President Calls for Enhanced Surgical Research Support at Millin Meeting

Professor Michael Kerin, president of the Royal College of Surgeons in Ireland (RCSI), has called for increased support for surgeons to strengthen the nation's surgical research capacity. His remarks preceded the annual Millin Meeting, a gathering of leading healthcare experts focused on integrating innovation and clinical trials into everyday surgical practice.

Toddler Diagnosed With Leukemia After Symptoms Dismissed as Winter Illness

Manraj Singh Hans, now seven, was diagnosed with acute lymphoblastic leukemia in February 2023 after a prolonged period during which his early symptoms were repeatedly misdiagnosed as common infections. His parents, Narinder Singh and Parm Hans, initially dismissed signs of illness as winter fatigue before blood in the child’s diaper prompted urgent medical intervention.

Change text size: